- DKK 380 million will be invested in the Kalundborg plant.
- The project will create 50 new jobs.
- The plant will be operational by Q1 2014.
- The investment will convert facilities for semaglutide production.
Investment and Job Creation
Novo Nordisk is investing an additional 380 million Danish kroner (approximately €51 million) in its Kalundborg plant in Denmark. This project will create 50 new production and engineering jobs in Kalundborg, where the company currently employs over 2,400 people.
Semaglutide Production
The investment will be used to convert manufacturing capacity in an existing facility to enable future production of semaglutide, a new treatment for type 2 diabetes. Semaglutide is a once-weekly GLP-1 analogue.
Operational Timeline
The converted plant is expected to be operational in the first quarter of 2014. Other ongoing investment projects at Novo Nordisk in Denmark include a new domicile in Bagsværd and a new facility in Kalundborg for the production of biopharmaceuticals such as haemophilia medicine and growth hormone. The investments in these projects amount to 2 billion kroner.
